VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-830-3031
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.36 million
Profitability
Miscellaneous
Employees108
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
How were VBI Vaccines' earnings last quarter?
VBI Vaccines Inc (NASDAQ:VBIV) released its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $0.64 million for the quarter, compared to analysts' expectations of $0.60 million. VBI Vaccines had a negative return on equity of 73.80% and a negative net margin of 1,582.45%. View VBI Vaccines' Earnings History.
When is VBI Vaccines' next earnings date?
What price target have analysts set for VBIV?
2 brokers have issued 12 month price objectives for VBI Vaccines' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate VBI Vaccines' stock price to reach $5.00 in the next year. This suggests a possible upside of 841.6% from the stock's current price. View Analyst Price Targets for VBI Vaccines.
What is the consensus analysts' recommendation for VBI Vaccines?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.
Has VBI Vaccines been receiving favorable news coverage?
Media coverage about VBIV stock has trended somewhat positive on Monday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. VBI Vaccines earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for VBI Vaccines.
Are investors shorting VBI Vaccines?
VBI Vaccines saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 3,510,000 shares, a drop of 23.0% from the August 30th total of 4,560,000 shares. Based on an average daily volume of 1,470,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 4.4% of the company's shares are short sold. View VBI Vaccines' Current Options Chain.
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Magenta Therapeutics (MGTA), Merus (MRUS), DURECT (DRRX), XBiotech (XBIT), ImmunoGen (IMGN), Innate Pharma (IPHYF), BioSpecifics Technologies (BSTC), Obseva (OBSV), Lexicon Pharmaceuticals (LXRX), CymaBay Therapeutics (CBAY), AC Immune (ACIU), CytomX Therapeutics (CTMX), Constellation Pharmaceuticals (CNST), Corbus Pharmaceuticals (CRBP) and Protagonist Therapeutics (PTGX).
What other stocks do shareholders of VBI Vaccines own?
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
- Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
- Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
- Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
- Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)
How do I buy shares of VBI Vaccines?
Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBIV stock can currently be purchased for approximately $0.53.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of $94.66 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. VBI Vaccines employs 108 workers across the globe.View Additional Information About VBI Vaccines.
What is VBI Vaccines' official website?
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]
MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
